These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34178661)

  • 1. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
    Marofi F; Al-Awad AS; Sulaiman Rahman H; Markov A; Abdelbasset WK; Ivanovna Enina Y; Mahmoodi M; Hassanzadeh A; Yazdanifar M; Stanley Chartrand M; Jarahian M
    Front Oncol; 2021; 11():673276. PubMed ID: 34178661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment.
    Navin I; Lam MT; Parihar R
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Zhang L; Meng Y; Feng X; Han Z
    Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.
    Luo W; Hoang H; Zhu H; Miller K; Mo X; Eguchi S; Tian M; Liao Y; Ayello J; Rosenblum JM; Marcondes M; Currier M; Mardis E; Cripe T; Lee D; Cairo MS
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39266215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
    Hojjatipour T; Sharifzadeh Z; Maali A; Azad M
    Hum Cell; 2023 Nov; 36(6):1843-1864. PubMed ID: 37477869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages and applications of CAR-expressing natural killer cells.
    Glienke W; Esser R; Priesner C; Suerth JD; Schambach A; Wels WS; Grez M; Kloess S; Arseniev L; Koehl U
    Front Pharmacol; 2015; 6():21. PubMed ID: 25729364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
    Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
    Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of natural killer immunotherapy in blood cancers and solid tumors.
    Sayegh M; Ma S; Yu J
    Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.